Robert Lustig: The Hidden Fat That Matters—Visceral Fat, Waist Size, and Key Biomarkers #fat #obese @Emerypharma
Robert Lustig: The Hidden Fat That Matters—Visceral Fat, Waist Size, and Key Biomarkers #fat #obese  @Emerypharma
Uploaded January 2025 | Updated September 2026, 2 weeks ago
Welcome to the Emery Pharma Speaker Series!

These shorts are designed to spotlight critical topics from our conversation with Dr. Robert Lustig, MD, a renowned expert in metabolism and public health. Dr. Lustig has an extraordinary ability to break down complex scientific concepts into simple, relatable ideas that anyone can understand.

In the main video, Dr. Lustig discusses the dramatic rise in Type 2 diabetes among children—virtually unheard of before 1990. In this compelling interview with Dr. Ron Najafi, CEO of Emery Pharma, he links this alarming trend to the widespread consumption of ultra-processed foods, particularly added sugars. Dr. Lustig explains that Type 2 diabetes, once an adult-only disease, now accounts for one-third of all diabetes cases in children, signaling a dire public health crisis fueled by modern dietary habits.

Dr. Lustig reveals that added sugars, especially fructose, act as chronic toxins that damage mitochondria and disrupt metabolism. He highlights how children are increasingly developing conditions previously exclusive to adults, such as fatty liver disease and Type 2 diabetes. Other harmful elements in ultra-processed foods—like trans fats, preservatives, and emulsifiers—further exacerbate metabolic dysfunction and inflammation, promoting chronic diseases in both children and adults.

He also delves into the distinction between metabolically healthy and unhealthy obesity. Subcutaneous fat, while cosmetically undesirable, is metabolically protective. However, visceral and liver fat pose serious health risks, regardless of weight. Dr. Lustig identifies waist circumference and fasting insulin levels as practical biomarkers for metabolic health, advocating for their routine use in medical assessments.

The discussion explores the controversial use of statins for cardiovascular disease prevention. While Dr. Lustig supports their use after a heart attack (secondary prevention), he challenges their widespread prescription for primary prevention, citing their limited effectiveness in reducing heart disease risk. He also warns that statins can impair mitochondrial function, raising the risk of diabetes and metabolic issues.

Dr. Lustig emphasizes the need for moderation in sugar consumption, advocating for whole fruits with their natural fiber intact. He explains that fiber slows sugar absorption and benefits gut health, contrasting sharply with processed foods and beverages that lack fiber and accelerate harmful metabolic effects. He calls for regulatory action to recognize added sugars as toxic food additives.

Additionally, the conversation covers artificial sweeteners, which, despite being calorie-free, still trigger insulin responses and contribute to weight gain. Dr. Lustig highlights persistent misconceptions about diet and metabolism in medical education and public policies, urging greater awareness and dietary reform to combat the root causes of these health crises.

Dr. Najafi enriches the discussion by connecting these insights to public health and pharmaceutical research, emphasizing their practical implications. Together, they stress the urgency of addressing modern dietary habits to mitigate the metabolic health challenges facing both children and adults.

To watch the full video, click here: youtu.be/YW9zJeaPKmU
Or simply click on the link at the bottom of this short. Enjoy!
Robert Lustig: The Hidden Fat That Matters—Visceral Fat, Waist Size, and Key Biomarkers #fat #obeseWhy Obesity Isn’t the Real Problem | Dr. Robert Lustig Exposes the Truth About Chronic DiseaseBill Wilson, MD: GLP-1 Drugs Reverse Insulin Resistance—The Master Switch to Fight Chronic DiseaseRobert Lustig: Why Insulin Sensitivity Matters More Than BMI #obesity #diabetiesPresentation at Exelixis Pharma. “Nitrosamine Challenges in Drug Development: Are You Prepared?”Bill Wilson, MD: GLP-1 Cuts Sugar Cravings—Breaking the Insulin Spike and Vicious Cycle of AddictionCelebrating Innovation, Compliance, and Collaboration-Emery Pharma at PDA West Coast’s Quality BallRobert Lustig, MD: How Fructose Fuels Fatty Liver, Oxidative Stress, and Metabolic Disease #fructoseBill Wilson, MD: GLPs May Reverse Carb Syndrome—Helping Patients Reach Zero and Sustain with DietRevolutionizing Antibiotic Testing: MIC, MBC & Time-Kill Assays Explained | Emery Pharma #antibioticRobert Lustig, MD Live @ the Emery Pharma Feb 13, 2026 2:30 PM PT join us on zoom see link comment:Bill Wilson, MD: GLP-1 as the Master Switch for Controlling Metabolic Syndrome and Disease
Emery Pharma |

Robert Lustig: The Hidden Fat That Matters—Visceral Fat, Waist Size, and Key Biomarkers #fat #obese

SHARE TO X SHARE TO REDDIT SHARE TO FACEBOOK WALLPAPER